Company intelligence / Profile preview

Kalytera Therapeutics

Manhattan Beach, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

The company was developing cannabidiol-based treatments for graft versus host disease in late-stage clinical trials with an ongoing Phase 2 clinical study in prevention of GVHD and expected to initiate a seamless Phase 2-3 pivotal registration study in treatment of acute GVHD. Later pivoted to developing R-107 for COVID-19 and viral infections.

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Salzman Group: License agreement for R-107 development and commercialization with license fee of $1.2 million and issuance of 130 million common shares

Beyond the preview

Go deeper on Kalytera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kalytera Therapeutics.

Explore the full profile